Brain Tumors in Children
Sold by Biblios, Frankfurt am main, HESSE, Germany
AbeBooks Seller since 10 September 2024
New - Soft cover
Condition: New
Ships from Germany to U.S.A.
Quantity: 4 available
Add to basketSold by Biblios, Frankfurt am main, HESSE, Germany
AbeBooks Seller since 10 September 2024
Condition: New
Quantity: 4 available
Add to basketPRINT ON DEMAND pp. 426.
Seller Inventory # 18376404145
This book is a comprehensive and up-to-date compendium of all aspects of brain tumors in children. After introductory chapters on the epidemiology of brain tumors, the book will provide readers with state-of-the art chapters on the principals of radiation therapy, neurosurgery and neuroimaging. Subsequent chapters discuss the biology and treatment of specific types of brain tumors. The concluding chapters present critical information relevant to survivorship, neurocognitive and other late effects, and the global challenges to better diagnosis and treatment of brain tumors in children. This book is co-authored by experts in the treatment of pediatric brain tumors. All of the authors are internationally recognized authorities and they offer an evidence-based consensus on the biology and treatment of brain tumors. This handbook has far-reaching applicability to the clinical diagnosis and management of brain tumors in children and will prove valuable to specialists, generalists and trainees alike.
Amar Gajjar, M.D., is Chair of the Department of Pediatric Medicine at St. Jude Children’s Research Hospital, Memphis, TN, USA. He has a long history at St. Jude, having undertaken a Pediatric Hematology/Oncology Fellowship there from 1989 to 1992 and then an additional year of Fellowship in Pediatric Neuro-Oncology. Since joining the Division of Neuro-Oncology as a Faculty Member in 1993, he has risen steadily through the academic ranks. He was appointed Division Director of Neuro-Oncology in 2002 and promoted to Full Member (Professor) in 2004. In 2005, he was appointed Co-Leader of the Neurobiology and Brain Tumor Program. In recognition of his academic excellence, in 2007 he was awarded the Scott and Tracie Hamilton Endowed Chair in Brain Tumor Research. He took up his present position in 2016. Nationally, Dr. Gajjar has served as the Chair of the Brain Tumor Committee in the Children’s Oncology Group (2009–17). Dr. Gajjar is principal or co-principal investigator in several innovative clinical trials of new treatments for a variety of brain tumors. He serves on the editorial boards of Neuro-Oncology and UpToDate and is a past editorial board member of the Journal of Clinical Oncology. Dr Gajjar has contributed significantly to the literature and has published work in various high impact journals.
Gregory H. Reaman, M.D. joined the Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration as the Associate Director of the Office of Oncology Drug Products in 2011. He is the Founding and Immediate Past Chair of the Children’s Oncology Group (COG) having served in this capacity from 2000 through 2010. The COG is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer. He is a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences and a member of theDivision of Hematology-Oncology at the Children’s National Medical Center in Washington, D.C., which he directed for more than 17 years. He has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query (PDQ), National Cancer Institute as well as www.PLWC.org (People Living with Cancer, now Cancer.net). He has served as an Associate Editor of Cancer and Leukemia and Lymphoma. He served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer. He has authored or co-authored more than 300 peer-reviewed publications and more than 25 books and book chapters. His research interests include the biology and therapy of childhood acute leukemia and new drug development for pediatric cancer.
Judy M. Racadio is a former Emergency Medicine physician who currently performs medical writing and editing for various academic medical, private medical, and corporate departments. She received her M.D. in 1992 from the University of Cincinnati. After completing her Emergency Medicine residency, she spent 6 years as an Assistant Professor of Emergency Medicine at the University of Cincinnati. Since leaving clinical medicine, she has provided editorial assistance for textbooks on pediatric leukemia, pediatric hematopoetic cell transplant and pediatric radiology. She has also written a series of continuing education modules for radiology technologists and has co-authored or provided editorial assistance for more than 60 peer-reviewed publications and book chapters. She is currently an Associate Editor for the Emergency Medicine Cardiac Research and Education Group (EMCREG).
Franklin O. Smith, III, M.D., FAAP, FACP, is Vice President for Medical Affairs at Medpace and is Professor of Medicine and Pediatrics at the University of Cincinnati Collegeof Medicine. He graduated from the University of South Carolina School of Medicine and completed postdoctoral training in pediatrics at the University of Florida and fellowship training in pediatric hematology/oncology at the University of Washington and the Fred Hutchinson Cancer Research Center. Prior to joining Medpace, Dr. Smith was the Clinical Director at the University of Cincinnati Cancer Institute. Previously, he was the Director, Division of Hematology/Oncology at Cincinnati Children's Hospital Medical Center and Vice-Chair of the Children's Oncology Group. He has authored more than 170 articles in medical and scientific journals. Dr. Smith is active with various national and international committees and societies in the field of research and clinical care. He serves on National Board of Directors for the Leukemia and Lymphoma Society, President of the Board of Managers for FACT Consulting Services, faculty for the ASCO/AACR Clinical Cancer Research Workshop, and a member ofthe NCI's Central Institutional Review Board. Dr. Smith has also served on standing and ad hoc committees for the FDA and NIH.
"About this title" may belong to another edition of this title.
If you are a consumer you can cancel the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
INFORMATION REGARDING THE RIGHT OF CANCELLATION
Statutory Right to cancel
You have the right to cancel this contract within 14 days for any reason.
The cancellation period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the the last good or the last lot or piece.
To exercise the right to cancel, you must inform us, Biblios, 47 Kaisetstrasse, 60329, frankfurt am main, hessen, Germany, of your decision to cancel this contract by a clear statement (e.g. a letter sent by post, fax or e-mail). You may use the attached model cancellation form, but it is not obligatory. You can also electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". If you use this option, we will communicate to you an acknowledgement of receipt of such a cancellation on a durable medium (e.g. by e-mail) without delay.
To meet the cancellation deadline, it is sufficient for you to send your communication concerning your exercise of the right to cancel before the cancellation period has expired.
Effects of cancellation
If you cancel this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to cancel with contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to us or Biblios, 47 Kaisetstrasse, 60329, frankfurt am main, Germany, without undue delay and in any event not later than 14 days from the day on which you communicate your cancellation from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of cancellation
The right of cancellation does not apply to:
Model withdrawal form
(complete and return this form only if you wish to withdraw from the contract)
To: (Biblios, 47 Kaisetstrasse, 60329, frankfurt am main, hessen, Germany)
I/We (*) hereby give notice that I/We (*) withdraw from my/our (*) contract of sale of the following goods (*)/for the provision of the following goods (*)/for the provision of the following service (*),
Ordered on (*)/received on (*)
Name of consumer(s)
Address of consumer(s)
Signature of consumer(s) (only if this form is notified on paper)
Date
* Delete as appropriate.
| Order quantity | 25 to 45 business days | 8 to 14 business days |
|---|---|---|
| First item | £ 8.63 | £ 16.23 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.